ICON PLC

ICON Hosts Investor Day and Updates Full Year 2024 Financial Guidance

Retrieved on: 
torsdag, maj 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Medical Devices, Professional Services, EST, ICLR, Webcast, ICON PLC

ICON plc , (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, will host its 2024 Investor Day today in New York City.

Key Points: 
  • ICON plc , (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, will host its 2024 Investor Day today in New York City.
  • The event will feature presentations from ICON’s executive team and provide further details on the strategic initiatives that will drive the near and long-term outlook for the company.
  • Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 - $8,720 million, representing a year over year increase of 4.4% to 7.4%.
  • Full-year 2024 adjusted earnings per share* guidance is now expected to be in the range of $14.75 - $15.25, an increase from the previous range of $14.65 - $15.15.

ICON plc to hold Investor Day Meeting on May 30, 2024

Retrieved on: 
måndag, maj 20, 2024
General Health, Professional Services, Health, Finance, ICLR, ICON PLC

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will hold an Investor Day which will take place on Thursday, May 30, 2024 in New York City, starting at 10am ET.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will hold an Investor Day which will take place on Thursday, May 30, 2024 in New York City, starting at 10am ET.
  • The event will include presentations from members of ICON’s executive team, and access to a live webcast will be made available in on the Investor section of our website.
  • It is expected that the presentations, followed by a question and answer session, will conclude at approximately 1pm ET.

Global Companion Diagnostics Research Report 2024-2029: $13.5+ Billion Market Analysis by Assays, Kits, Reagents, System, Software & Services, PCR, NGS, ISH, IHC - ResearchAndMarkets.com

Retrieved on: 
måndag, maj 13, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, NGS, ChromeOS, Assay, Region, USD, ISH, Danaher Corporation, Sysmex Corporation, Software, Government, Colorectal cancer, Pulse, Abbott Laboratories, Drug development, ICON PLC, Lung, Cancer, Growth, Research, CVD, Incidence, Biomarker, IHC, BioMérieux, Agilent Technologies, Illumina, Inc., PCR

The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.

Key Points: 
  • The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.
  • The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics market and its subsegments.
  • Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users.
  • In 2023, pharmaceutical & biotechnology companies stood out as the primary users of companion diagnostics within the market.

ICON releases its ICON Cares 2023 Report

Retrieved on: 
torsdag, maj 9, 2024
Research, Environment, Finance, Clinical Trials, Professional Services, Sustainability, DEI (Diversity, Equity and Inclusion), Health, Environmental, Social and Governance (ESG), Science, F-1, Health equity, F-4, Mentorship, ICLR, CSR, Thurgood Marshall College Fund, S-8, Female, STEM, Real-time, Gold, Novartis, Trinity College, ICON PLC, Patient, ESG, National Medical Association, Trinity College Dublin, Dublin City University, F-3, Clinical trial, Student, Merck, Sanofi, Digital platform, Financial Times, Beacon of Hope, Pharmaceutical industry

ICON plc , (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report .

Key Points: 
  • ICON plc , (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report .
  • This outlines how the company is delivering on its ESG, diversity, inclusion and belonging, and CSR goals, as delivered through its ICON Cares program.
  • In recognition of its efforts, in 2023, ICON achieved gold medal status from EcoVadis, a leading provider of business sustainability ratings.
  • Most recently, ICON has been named by the Financial Times and Statista as one of Europe’s Climate Leaders in 2024.

Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
onsdag, maj 1, 2024
Deployment, Clinical trial, Investment, Safety, ICON, Machine learning, QIAGEN, Data and information visualization, Collection, Table, Research, Artificial intelligence, Component, ICON PLC, Intelligence, Drug discovery, ChromeOS, Patient, Data collection, Data management, SGS, Health, Drug development, Biomarker, Growth, Pharmaceutical industry

PUNE, India, April 30, 2024 /PRNewswire/ -- The report titled " Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment - Global Forecast 2024-2030 " is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.

Key Points: 
  • PUNE, India, April 30, 2024 /PRNewswire/ -- The report titled " Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment - Global Forecast 2024-2030 " is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.
  • Clinical trial analytics services are revolutionizing the landscape of medical research and drug development across the globe by utilizing cutting-edge data analytics and statistical methodologies to offer invaluable insights from clinical trial data.
  • The Americas lead the market with robust clinical trial activity, supported by Europe's push for more transparent and unified trial regulations.
  • "Dive into the Clinical Trial Analytics Services Market Landscape: Explore 184 Pages of Insights, 574 Tables, and 26 Figures"

Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
onsdag, maj 1, 2024
Deployment, Clinical trial, Investment, Safety, ICON, Machine learning, QIAGEN, Data and information visualization, Collection, Table, Research, Artificial intelligence, Component, ICON PLC, Intelligence, Drug discovery, ChromeOS, Patient, Data collection, Data management, SGS, Health, Drug development, Biomarker, Growth, Pharmaceutical industry

PUNE, India, April 30, 2024 /PRNewswire/ -- The report titled " Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment - Global Forecast 2024-2030 " is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.

Key Points: 
  • PUNE, India, April 30, 2024 /PRNewswire/ -- The report titled " Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment - Global Forecast 2024-2030 " is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.
  • Clinical trial analytics services are revolutionizing the landscape of medical research and drug development across the globe by utilizing cutting-edge data analytics and statistical methodologies to offer invaluable insights from clinical trial data.
  • The Americas lead the market with robust clinical trial activity, supported by Europe's push for more transparent and unified trial regulations.
  • "Dive into the Clinical Trial Analytics Services Market Landscape: Explore 184 Pages of Insights, 574 Tables, and 26 Figures"

ICON Announces Pricing of USD 2 Billion Notes

Retrieved on: 
tisdag, april 30, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Other Health, Internet, Health, Data Management, 3rd Floor, European Economic Area, EDGAR, Medicine, Person, Prospectus, Communication, Madison Avenue, Capital market, Financial services, Telephone, Surety, ICLR, Broadridge Financial Solutions, EEA, FSMA, Government, Attention, Investment, Note, Sale, PRA Health Sciences, Senior, ICON PLC, Failure, Register, Credit, Grand duchy, Security (finance)

ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).

Key Points: 
  • ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).
  • The offering is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.
  • This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, including the Notes.
  • With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 102 locations in 54 countries as at March 31, 2024.

ProPharma Announces Changes to Its Executive Leadership Team

Retrieved on: 
torsdag, april 11, 2024
Odyssey, ICON PLC, Lead, CMO, Social media, General counsel, Merz Pharma, Shaw, Heart, RCO, PRA Health Sciences, Private practice, Research, GSK, Marketing, CIO, Labcorp, Global marketing, Icon, CPG, Global health, Management

RALEIGH, N.C., April 11, 2024 /PRNewswire/ -- ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer (CIO) and Andrew Shaw as General Counsel. In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing.

Key Points: 
  • In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing.
  • "We are thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, Chief Executive Officer.
  • "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale."
  • Wroblewski is a highly accomplished, solutions-focused information executive with more than 20 years of experience in healthcare data and analytics.

ProPharma Announces Changes to Its Executive Leadership Team

Retrieved on: 
onsdag, april 10, 2024
Odyssey, ICON PLC, Lead, CMO, Social media, General counsel, Merz Pharma, Shaw, Heart, RCO, PRA Health Sciences, Private practice, Research, GSK, Marketing, CIO, Labcorp, Global marketing, Icon, CPG, Global health, Management

RALEIGH, N.C., April 10, 2024 /PRNewswire-PRWeb/ -- ProPharma https://www.propharmagroup.com/, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners https://www.odysseyinvestment.com/ is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer (CIO) and Andrew Shaw as General Counsel. In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing.

Key Points: 
  • "We're thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, CEO.
  • "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale."
  • "We are thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, Chief Executive Officer.
  • "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale."

Healthcare Analytical Testing Services Market Worth $12.6 billion | MarketsandMarkets™

Retrieved on: 
onsdag, april 10, 2024
Merck Group, Pulse, Investment, Steris, ICON PLC, Parexel, Health care, Research, Sartorius AG, Wuxi, Intertek, Legal Entity Identifier, Labcorp, Region, Acquisition, Charles River Laboratories, SGS, Eurofins Scientific, INC, Market development

This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.

Key Points: 
  • This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.
  • This strategic acquisition strengthens SGS's presence in key market segments and enhances its ability to deliver comprehensive services to clients worldwide.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=108923833
    Healthcare Analytical Testing Services Market - Key Benefits of Buying the Report:
    This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.